What this trial measures

• Frequency of arrhythmias7 days of wear

  Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the frequency of arrhythmias.

• Frequency of atrial fibrillation7 days of wear

  Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the frequency of atrial fibrillation.

• Frequency of atrial flutter7 days of wear

  Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the frequency of atrial flutter.

• Density of premature ventricular contractions (PVCs)7 days of wear

  Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the density of PVCs (percentage of total heartbeats that are PVCs).

• Frequency of ventricular tachycardia7 days of wear

  Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the frequency of ventricular tachycardia.

• Heart rate7 days of wear

  Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine heart rate.

• Standard deviation of beat-to-beat intervals (SDNN)7 days of wear

  Standard deviation of beat-to-beat intervals (SDNN) is a heart rate variability (HRV) time domain measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.

• Root mean square of successive differences (RMSSD)7 days of wear

  Root mean square of successive differences (RMSSD) is a heart rate variability (HRV) time domain measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.

• Low frequency power7 days of wear

  Low frequency power (LF, 0.04 - 0.15 Hz) is a heart rate variability (HRV) frequency domain measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.

• High frequency power7 days of wear

  High frequency power (HF, 0.15 - 0.4 Hz) is a heart rate variability (HRV) frequency domain measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.

• Log-transformed QT variance (logQTv)7 days of wear

  Log-transformed QT variance (logQTv) s a QT variability (QTV) measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.

• Beat-to-beat QT variability index (QTVI)7 days of wear

  Beat-to-beat QT variability index (QTVI) is a QT variability (QTV) measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.

• Presence of obstructive sleep apneaOne night

  The presence of comorbid obstructive sleep apnea and/or nocturnal hypoxemia, will be evaluated with a home sleep study test device (HST) worn during the second or third study day

• Presence of nocturnal hypoxemiaOne night

  The presence of comorbid obstructive sleep apnea and/or nocturnal hypoxemia, will be evaluated with a home sleep study test device (HST) worn during the second or third study day

• 24-hour ambulatory blood pressure monitor (ABPM)24 hours

  Blood pressure (diastolic and systolic) will be assessed using a 24-hour ABPM worn during the 24-hour period following the HST.

• High sensitivity C-reactive protein (hs-CRP)Baseline

  This inflammatory marker will be measured during laboratory testing.

• Posttraumatic Stress Disorder Checklist for Diagnostic and Statistics Manual of Mental Disorder 5 (PCL-5)Baseline

  The severity of Posttraumatic Stress Disorder (PTSD) symptoms will be assessed by the PCL-5 20-question survey. Total scores range from 0 - 80, with higher scores indicating greater PTSD symptom severity.

• 8-item Patient Health Questionnaire depression scale (PHQ-8)Baseline

  The severity of depressive symptoms will be measured by the eight-question PHQ-8 survey. Total scores range from 0 - 24, with with higher scores indicating greater depressive symptom severity.

• Brief Dissociative Experience Scale (DES-B)Baseline

  Severity of dissociative experiences will be assessed using the 8-item DES-B survey. Total scores range from 0 - 32, with with higher scores indicating greater dissociative experience severity.

• Pittsburgh Sleep Quality Index (PSQI)Baseline

  Participant-reported sleep characteristics will be assessed using the 19-item Pittsburgh Sleep Quality Index (PSQI). Total scores range from 0 - 21, with higher scores indicating worse sleep quality.

• Epworth Sleepiness Scale (ESS)Baseline

  Participant-reported sleep characteristics will be assessed using the 8-item Epworth Sleepiness Scale (ESS). Total scores range from 0 - 24, with higher scores indicating increased daytime sleepiness.

• Insomnia Severity Index (ISI)Baseline

  Participant-reported sleep characteristics will be assessed using the 7-item Insomnia Severity Index (ISI). Total scores range from 0 - 28, with higher scores indicating increased insomnia symptoms.

• Berlin Sleep QuestionnaireBaseline

  Participant-reported sleep characteristics will be assessed using the 11-item Berlin Sleep Questionnaire. Scores will be calculated to determine if participants are "High Risk" or "Low Risk" for sleep apnea.

• Body Mass IndexBaseline

  Height and weight will be measured during laboratory visit and combined to report BMI in kg/m\^2.

• Blood PressureBaseline

  Blood pressure (diastolic and systolic) will be recorded at the time of laboratory visit

• Hemoglobin A1C (HBA1C)Baseline

  This laboratory test will be used to assess overall health outcomes.

• Alanine aminotransferase (ALT/SGPT)Baseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Albumin:globulin (A:G) ratioBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Albumin, serumBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Alkaline phosphatase, serumBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Aspartate aminotransferase (AST/SGOT)Baseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Bilirubin, totalBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Blood urea nitrogen (BUN)Baseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Blood urea nitrogen (BUN):creatinine ratioBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Calcium, serumBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Carbon dioxide, totalBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Chloride, serumBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Creatinine, serumBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Estimated glomerular filtration rate (eGFR) calculationBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Globulin, totalBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Glucose, serumBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Potassium, serumBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Protein, total, serumBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Sodium, serumBaseline

  This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.

• Cystatin C with estimated glomerular filtration rate (eGFR)Baseline

  This laboratory test will be used to assess overall health outcomes.

• Cholesterol, totalBaseline

  This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.

• High-density lipoprotein (HDL) cholesterolBaseline

  This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.

• Low-density lipoprotein (LDL) cholesterol (calculation)Baseline

  This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.

• TriglyceridesBaseline

  This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.

• Very low-density lipoprotein (VLDL) cholesterol (calculation)Baseline

  This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.

• Albumin/creatinine ratio, random urineBaseline

  This laboratory test will be used to assess overall health outcomes.

• N-terminal pro b-type natriuretic peptide (NT-proBNP)Baseline

  This laboratory test will be used to assess overall health outcomes.